

# Design and Synthesis of a 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> Dimer as a Potential Chemical Inducer of Vitamin D Receptor Dimerization


José Pérez Sestelo,<sup>†</sup> Antonio Mouriño,<sup>‡</sup> and Luis A. Sarandeses<sup>\*,†</sup>

*Departamento de Química Fundamental e Industrial, Universidade da Coruña, E-15071 A Coruña, Spain, and Departamento de Química Orgánica y Unidad Asociada al C.S.I.C., Universidade de Santiago de Compostela, E-15706 Santiago de Compostela, Spain*

qfsarand@udc.es


Received July 28, 1999

## ABSTRACT



A dimer comprising two 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> units linked by an alkyl side chain at C-11 was synthesized with a view to the simultaneous binding of two vitamin D receptor (VDR) molecules and the consequent induction of VDR dimerization. The short, convergent synthesis uses a stereoselective cuprate addition to introduce the linking side chain and a key ruthenium olefin metathesis as the dimerization step.

1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> (calcitriol, **1c**) (Figure 1), the hormonally active form of vitamin D<sub>3</sub> (**1a**),<sup>1</sup> besides regulating the metabolism of calcium and phosphorus, promotes cell differentiation, inhibits the proliferation of tumor cells, and induces some biological functions related to the immune system.<sup>2</sup> Calcitriol acts in the cell nucleus by binding to the vitamin D receptor (VDR), a member of the nuclear receptor superfamily that can interact with DNA as a homodimer



**Figure 1.** Vitamin D<sub>3</sub>, 25-(OH)-D<sub>3</sub>, and 1 $\alpha$ ,25-(OH)<sub>2</sub>-D<sub>3</sub>.

(VDR–VDR) or a heterodimer with the retinoid X receptor (VDR–RXR).<sup>3</sup> The role of dimeric VDR structures in activation of gene transcription is not clear.

<sup>†</sup> Universidade da Coruña.


<sup>‡</sup> Universidade de Santiago de Compostela.

(1) Vitamin D<sub>3</sub> is transformed to 1 $\alpha$ ,25-(OH)<sub>2</sub>-D<sub>3</sub> (**1c**) through 25-(OH)-D<sub>3</sub> (**1b**) by two specific enzymatic hydroxylations.

(2) For a general review of vitamin D chemistry and biology, see: (a) *Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone*; Norman, A. W., Bouillon, R., Thomasset, M., Eds; Vitamin D Workshop, Inc.: Riverside, CA, 1997. (b) Zhu, G.-D.; Okamura, W. H. *Chem. Rev.* **1995**, 95, 1877.

Recently, it has been found possible to influence many cell processes involving proteinic receptors by means of dimeric molecules with two protein-binding regions, which can act by facilitating the dimerization of the ligand receptor and have become known as chemical inducers of dimerization (CIDs).<sup>4</sup> This effect is based on the importance that proximity and orientation have in the protein function during the information transfer process. The few CIDs that have been synthesized to date include the dimers of the immunosuppressive agents FK506 (FK1012) and cyclosporin A [(CyA)<sub>2</sub>].<sup>5</sup> In this Letter we describe the synthesis of the first calcitriol dimer, which we designed to bind two molecules of VDR and hence, hopefully, facilitate the formation of VDR–VDR dimers with a view to the exploration and possible exploitation of their role in transcription control.

The design of the calcitriol dimer took into account the fact that the triene system and the hydroxyl groups at positions 1 $\alpha$  and 25 are crucial for the biological activity of calcitriol<sup>6</sup> and that the incorporation of new functional groups alters its biological activity dramatically.<sup>3,7</sup> These considerations, and the absence of other functional groups in the vitamin D structure, ruled out direct dimerization, and we therefore decided to construct a molecule consisting of two calcitriol moieties linked by an alkyl chain attached to each calcitriol at ring C, which is probably the least active part of the vitamin D structure (Scheme 1). Specifically, we aimed




to obtain dimer **2** by dimerization of the alkenylic vitamin D analogue **3** using an olefin metathesis reaction.<sup>8</sup> The retrosynthetic analysis includes the formation of **3** from

(3) Freedman, L. P.; Lemon, B. D. In *Vitamin D*; Feldman, D., Glorieux, F. H., Pike, J. W., Eds.; Academic Press: San Diego, 1997; Chapter 9, pp 127–148.


ketone **4** and phosphine oxide **5** using the Wittig–Horner approach<sup>9</sup> and the introduction of the olefinic side chain by cuprate chemistry.<sup>10</sup>

The synthesis of **3** starts with known ester **6**.<sup>11</sup> Addition of MeLi (3 equiv), followed by oxidation with PDC and protection with TESOTf at –78 °C, afforded ketone **7** (73%, three steps) (Scheme 2). Treatment of **7** under Saegusa



reaction conditions,<sup>12</sup> followed by reaction of the resulting enone **8** with the cuprate derived from 4-bromobutene, gave **4** in 90% yield as the only diastereoisomer detected by <sup>1</sup>H NMR spectroscopy.

Formation of the vitamin D triene system was achieved in 87% yield by the reaction between ketone **4** and the ylide derived from phosphonium oxide **5** containing ring A,<sup>13</sup> to give the protected vitamin D analogue **3** (Scheme 3). Olefin



metathesis of **3** with Grubbs's catalyst<sup>14</sup> (10 mol %) in CH<sub>2</sub>Cl<sub>2</sub> at room temperature afforded, after 4 h, an inseparable mixture of **3** and its dimer with loss of ethylene.

Treatment of the mixture with TBAF in THF allowed the isolation of dimer **9** as a 5:1 mixture of alkene isomers (35%) and deprotected vitamin **3** (52%). Remarkably, the olefin metathesis does not affect the triene system. Unfortunately, attempts to obtain calcitriol dimer **2** by chemoselective hydrogenation of the nonconjugated double bond led to the fully saturated dimer.

To circumvent this problem we decided to carry out the olefin metathesis reaction and hydrogenation before construction of the triene system. Treatment of olefinic ketone **4** with catalytic amounts of  $(\text{Cy}_3\text{P})_2\text{Cl}_2\text{Ru}=\text{CHPh}^{14}$  (10 mol %) provided dimeric ketone **10** as a mixture of alkene isomers (6:1) in 46% yield together with recovered starting ketone (50%) (Scheme 4). Catalytic hydrogenation of the olefinic mixture **10** for 12 h at atmospheric pressure using a rhodium catalyst gave dimeric ketone **11** in quantitative yield. Treatment of **11** with the ylide derived from phosphonium


oxide **5** (2.2 equiv) led to stereoselective formation of protected calcitriol dimer **2a** in excellent yield (85%). Removal of the six silyl groups with TBAF in THF (rt, 24 h) afforded the desired calcitriol dimer **2** in 74% yield.

In conclusion, we have prepared the first dimer containing two calcitriol moieties, in each of which the VDR-binding region is unobstructed. The synthesis is short and convergent and should allow the preparation of an entire family of dimeric vitamin D structures. The length of the linker could be modulated to optimize binding with the receptor and the biological response associated with the binding of two VDR molecules. Biological evaluation of dimer **2** in terms of its VDR binding, dimerization induction capacities, and influence on signal transduction mechanisms are currently underway.

**Acknowledgment.** We thank the DGES (Spain, PM97-0166), Xunta de Galicia (XUGA 10305A98), and the University of A Coruña for financial support. J.P.S. thanks the Spanish Ministry of Education and Culture for a research grant. We also thank Mrs. Paulina Freire for reproducing some experiments and Mr. Carlos Gregorio for preparation of the A ring phosphine oxide.

**Supporting Information Available:** Complete characterization data ( $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR and mass spectral data) for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL990878Z



- (4) (a) Driver, S. T.; Schreiber, S. L. *J. Am. Chem. Soc.* **1997**, *119*, 5106.
- (b) Ho, S. N.; Biggar, S. R.; Spencer, D. M.; Schreiber, S. L.; Crabtree, G. R. *Nature* **1996**, *382*, 822. (c) Spencer, D. M.; Wandless, T. J.; Schreiber, S. L.; Crabtree, G. R. *Science* **1993**, *262*, 1019.
- (5) (a) Pruschy, M. N.; Spencer, D. M.; Kapoor, T. M.; Miyaki, H.; Crabtree, G. R.; Schreiber, S. L. *Chem. Biol.* **1994**, *1*, 163. (b) Belshaw, P. J.; Spencer, D. M.; Crabtree, G. R.; Schreiber, S. L. *Chem. Biol.* **1996**, *3*, 731.
- (6) Calverley, M. J.; Jones, J. In *Antitumor Steroids*; Blickenstaff, R. T., Ed.; Academic Press: San Diego, 1992; Chapter 7, pp 193–270.
- (7) Bouillon, R.; Okamura, W. H.; Norman, A. W. *Endocrine Rev.* **1995**, *16*, 200.
- (8) Olefin metathesis has proved to be useful for homodimerization, see: Clark, T. D.; Gadhiri, M. R. *J. Am. Chem. Soc.* **1995**, *117*, 12364 and ref 4a.
- (9) Lythgoe, B.; Moran, T. A.; Nambudiry, M. E. N.; Ruston, S.; Tideswell, J.; Wright, P. W. *Tetrahedron Lett.* **1975**, 3863.
- (10) (a) Torneiro, M.; Fall, Y.; Castedo, L.; Mourino, A. *Tetrahedron Lett.* **1992**, *33*, 105. (b) D'Halleweyn, C.; Van Haver, D.; Van der Eycken, J.; De Clerq, P.; Vandewalle, M. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 477.
- (11) Mascareñas, J. L.; Pérez Sestelo, J.; Castedo, L.; Mourino, A. *Tetrahedron Lett.* **1991**, *32*, 2813.
- (12) Ito, Y.; Hirao, T.; Saegusa, T. *J. Org. Chem.* **1978**, *43*, 1011.
- (13) Mourino, A.; Torneiro, M.; Vitale, C.; Fernández, S.; Pérez Sestelo, J.; Anné, S.; Gregorio, C. *Tetrahedron Lett.* **1997**, *38*, 4713.
- (14) Schwab, P.; Grubbs, R. H.; Ziller, J. W. *J. Am. Chem. Soc.* **1996**, *118*, 100.